Patients receive 4 cycles of RP, followed by consolidation with 6 cycles of MPR. Finally, maintenance therapy follows, with RP administered until any sign of disease progression.
STUDY OBJECTIVES:
Primary objectives: - Determine whether the association of RP followed by MPR as induction treatment is safe and induce a significant rate of PR (and CR) in elderly patients with newly diagnosed symptomatic multiple myeloma patients who are 65 years of age or older
Secondary objectives: - Determine progression free survival (PFS), time to progression (TTP) and overall survival (OS)
- Determine whether responses obtained with RP - MPR treatment, are associated with a prolongation of PFS, in comparison with non-responding patients
STUDY POPULATION:
Newly diagnosed MM patients who are older than 65 years of age
STUDY DRUGS:
Lenalidomide
Prednisone
Melphalan
TOTAL SAMPLE SIZE: 46
STUDY DURATION: 36 months